Protagenic Therapeutics, Inc. - PTIX Forward P/S Multiple
Cold chain optimization for peptide delivery ensures operational stability, establishing a foundation for Tcap patent protection and FDA compliance for Protagenic Therapeutics (PTIX). The forward P/S ratio trend on GURU.Markets reflects this resilience, where represents the current metric. Completing the picture is the development of innovative antidepressants that restore the brain's natural balance without side effects.
Analytical breakdowns for protagenic.com (PTIX)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Protagenic Therapeutics|PTIX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Protagenic Therapeutics, Inc.|PTIX - Aggregate Debt Obligations|Debts to Book Capitalization Protagenic Therapeutics, Inc.|PTIX - Long-Term Debt|Company Short-Term Debt Protagenic Therapeutics|Quick Ratio protagenic.com
- financial results and valuation multiples details:
PTIX - Net Profit|Expected Profit Protagenic Therapeutics|PTIX - Market Cap to Net Income|Forward P/E Multiple Protagenic Therapeutics, Inc.|PTIX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Protagenic Therapeutics, Inc.|PTIX - Operating profit EBITDA|Net earnings per share for the last 12 months Protagenic Therapeutics|PTIX - Earnings per share for the last four quarters|Quarterly EPS earnings growth protagenic.com|PTIX - Expected net earnings per share growth this year|Earnings growth forecast for next year Protagenic Therapeutics
- sales and revenue data:
Summary company analysis:Protagenic PTIX
By outsourcing production and clinical trials, Protagenic Therapeutics (PTIX) minimizes capital expenditures, focusing instead on intellectual capital. The expected P/S metric reflects the market valuation of future revenue streams relative to market capitalization, allowing investors to assess the speed at which scientific developments convert into commercial success and to identify signs of asset overvaluation based on this trend.
Competitor analysis
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|Regencell - Forward P/S Multiple|Market Cap to Expected Sales Ratio Axsome Corp AXSM|ACAD: Forward P/S Multiple|Forward Price-to-Revenue Multiple xenon-pharma.com|Forward Price-to-Revenue Multiple VKTX|SUPN: Forward Price to Sales|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Price to Expected Revenue Ratio DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward Price to Sales BHVN|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Trevi Therapeutics Inc|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Anavex Life Sciences Corp - Forward Price to Sales|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward P/S Multiple Prothena Corporation|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|ANNX: Future Price to Revenue|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU: Forward Price-to-Revenue Multiple|VYGR - Forward P/S Multiple|NMRA (Neumora Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|SCLX: Price to Expected Revenue Ratio|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|Alpha Cognition Corp (ACOG) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CGTX|Forward Price-to-Revenue Multiple inhibikase.com IKT|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Market Cap to Expected Sales Ratio Assertio Holdings (ASRT)|COYA - Price-to-Projected Revenue Ratio|Future Price to Revenue VTGN|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|ABOS: Price to Expected Revenue Ratio|CRVO (CervoMed) - Forward P/S Multiple|Alterity Therapeutics Ltd (ATHE) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CLNN (Clene Inc.)|pepgen.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|RLMD: Market Cap to Projected Revenue|Annovis Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience Inc) - Forward Price-to-Revenue Multiple|Klotho Neurosciences (KLTO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|RVPH: Forward Price to Sales|Price-to-Projected Revenue Ratio MetaVia Inc (MTVA)|NRXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Helius Medical Technologies HSDT|PASG (Passage Bio Inc.) - Future Price to Revenue|NEUP - Price-to-Projected Revenue Ratio|Forward Price to Sales NERV (minervaneurosciences.com)|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Addex Therapeutics Ltd. (ADXN)|Forward Price-to-Revenue Multiple ALZN|CYCN (Cyclerion) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Forward P/S Multiple cortigent.com (CRGT)|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Projected Price to Revenue Brainstorm Cell Therapeutics Inc.|Cara Therapeutics, Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Chromocell|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ITCI|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Marinus Pharmaceuticals Inc (MRNS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NKGN|Forward Price-to-Revenue Multiple NeuroBo Pharma NRBO|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales SNPX|TRVN: Forward Price-to-Revenue Multiple|Vigil Neuroscience - Price to Expected Revenue Ratio|WENA: Forward P/S Multiple|Cerevel Corp - Forward Price to Sales
